Cargando…

The management of polycystic liver disease by tolvaptan

Detalles Bibliográficos
Autores principales:	Takenaka, Tsuneo, Miura, Soichiro, Kitajima, Masaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940483/ https://www.ncbi.nlm.nih.gov/pubmed/31189297 http://dx.doi.org/10.3350/cmh.2019.0026

Ejemplares similares

Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease
por: Mizuno, Hiroki, et al.
Publicado: (2017)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Raynaud's phenomenon triggered by the vasopressin V(2) receptor antagonist tolvaptan in a patient with autosomal dominant polycystic kidney disease and Sjögren's syndrome
por: Roca Oporto, F J, et al.
Publicado: (2021)

Birth of two healthy girls following preimplantation genetic diagnosis and gestational surrogacy in a rapidly progressive autosomal dominant polycystic kidney disease case using tolvaptan
por: Peces, Ramón, et al.
Publicado: (2021)

Therapy with the Combination of Tolvaptan and Furosemide for Refractory Edema in Nephrotic Syndrome
por: Meena, Jitendra, et al.
Publicado: (2020)

Tolvaptan should be used very carefully in very elderly patients
por: Kahraman, Fatih, et al.
Publicado: (2018)

Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients
por: Bargagli, Matteo, et al.
Publicado: (2021)

Glomerular filtration rate is the main predictor of urine volume in autosomal dominant polycystic kidney disease patients treated with tolvaptan when daily osmolar excretion is expressed as urinary osmolality/creatinine ratio
por: Borrego Utiel, Francisco José, et al.
Publicado: (2020)

Practical approaches to the management of autosomal dominant polycystic kidney disease patients in the era of tolvaptan
por: Müller, Roman-Ulrich, et al.
Publicado: (2018)

Tolvaptan treatment for severe neonatal autosomal-dominant polycystic kidney disease
por: Gilbert, Rodney D., et al.
Publicado: (2017)

Safety Profile of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease
por: Bellos, Ioannis
Publicado: (2021)

Optimal Patient Selection and Treatment Timing for Tolvaptan Therapy Following Cardiovascular Surgery
por: Horie, Kotaro, et al.
Publicado: (2023)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients Treated With Tolvaptan
por: Anderegg, Manuel A., et al.
Publicado: (2020)

Tolvaptan: Clinical Evidence for Slowing the Progression of Autosomal Dominant Polycystic Kidney Disease
por: Magistroni, Riccardo
Publicado: (2018)

Long-term Tolvaptan Treatment of Autosomal Dominant Polycystic Kidney Disease in Korea
por: Kim, Ha Yeon, et al.
Publicado: (2018)

Comment on: Benefits of tolvaptan on early dyspnea relief in patients with acute heart failure: A meta‐analysis
por: Yin, Cong, et al.
Publicado: (2023)

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
por: Gibson, Andrew, et al.
Publicado: (2020)

Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
por: Sans-Atxer, Laia, et al.
Publicado: (2018)

Tolvaptan for Primary Aldosteronism and Autosomal Dominant Polycystic Kidney Disease: A Case Report
por: Kunizawa, Kyohei, et al.
Publicado: (2018)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

Utility of ultrasonography for predicting indications for tolvaptan in patients with autosomal dominant polycystic kidney disease
por: Iijima, Hiroko, et al.
Publicado: (2022)

Creatine Kinase Elevation in Autosomal Dominant Polycystic Kidney Disease Patients on Tolvaptan Treatment
por: Rodríguez-Espinosa, Diana, et al.
Publicado: (2023)

Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
por: Kim, Yaerim, et al.
Publicado: (2023)

Tolvaptan for Fluid Management in Living Donor Liver Transplant Recipients
por: Imai, Shunichi, et al.
Publicado: (2018)

TIMING AND TREATMENT OPTIONS IN ADULT POLYCYSTIC LIVER DISEASE: A RARE FAMILIAR CASE AS EXAMPLE
por: SALCEDA, Juan Antonio, et al.
Publicado: (2018)

Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database
por: Watkins, Paul B., et al.
Publicado: (2015)

Long-Term Effects of High-Dose Tolvaptan for Autosomal Dominant Polycystic Kidney Disease Patients
por: Nakatani, Shinya, et al.
Publicado: (2020)

Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease
por: Grantham, Jared J., et al.
Publicado: (2017)

Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
por: Lanke, Shankar, et al.
Publicado: (2019)

Autosomal Recessive Polycystic Kidney Disease
por: Salati, Sajad Ahmad
Publicado: (2014)

Polycystic ovarian disease and associated factors
por: Thulkar, Jyoti, et al.
Publicado: (2016)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Evaluating the impact of a Risk Evaluation and Mitigation Strategy with tolvaptan to monitor liver safety in patients with autosomal dominant polycystic kidney disease
por: Estilo, Alvin, et al.
Publicado: (2022)

Author's Reply: How to Demonstrate the Impact of Cardiac Rehabilitation on Cardio-renal Protection
por: Kitajima, Ken, et al.
Publicado: (2019)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Use of diffusion-weighted magnetic resonance imaging in the management of infected renal cyst in polycystic kidney disease
por: Kale, P. G., et al.
Publicado: (2015)

The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure
por: Otsuka, Tomoyuki, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_48tn168cj1u5kf3c5oigrh8vjf